1. Home
  2. RAPT vs GDTC Comparison

RAPT vs GDTC Comparison

Compare RAPT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RAPT
  • GDTC
  • Stock Information
  • Founded
  • RAPT 2015
  • GDTC 2018
  • Country
  • RAPT United States
  • GDTC Singapore
  • Employees
  • RAPT N/A
  • GDTC N/A
  • Industry
  • RAPT Biotechnology: Pharmaceutical Preparations
  • GDTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • RAPT Health Care
  • GDTC Health Care
  • Exchange
  • RAPT Nasdaq
  • GDTC Nasdaq
  • Market Cap
  • RAPT 30.8M
  • GDTC 33.4M
  • IPO Year
  • RAPT 2019
  • GDTC 2023
  • Fundamental
  • Price
  • RAPT $0.89
  • GDTC $2.37
  • Analyst Decision
  • RAPT Hold
  • GDTC Buy
  • Analyst Count
  • RAPT 10
  • GDTC 1
  • Target Price
  • RAPT $5.00
  • GDTC $5.00
  • AVG Volume (30 Days)
  • RAPT 386.3K
  • GDTC 24.9K
  • Earning Date
  • RAPT 11-12-2024
  • GDTC 01-01-0001
  • Dividend Yield
  • RAPT N/A
  • GDTC N/A
  • EPS Growth
  • RAPT N/A
  • GDTC N/A
  • EPS
  • RAPT N/A
  • GDTC N/A
  • Revenue
  • RAPT N/A
  • GDTC $330,254.00
  • Revenue This Year
  • RAPT N/A
  • GDTC $14.71
  • Revenue Next Year
  • RAPT N/A
  • GDTC N/A
  • P/E Ratio
  • RAPT N/A
  • GDTC N/A
  • Revenue Growth
  • RAPT N/A
  • GDTC N/A
  • 52 Week Low
  • RAPT $0.82
  • GDTC $1.20
  • 52 Week High
  • RAPT $27.35
  • GDTC $5.50
  • Technical
  • Relative Strength Index (RSI)
  • RAPT 36.23
  • GDTC 45.29
  • Support Level
  • RAPT $0.84
  • GDTC $2.43
  • Resistance Level
  • RAPT $1.18
  • GDTC $3.00
  • Average True Range (ATR)
  • RAPT 0.10
  • GDTC 0.41
  • MACD
  • RAPT 0.01
  • GDTC -0.03
  • Stochastic Oscillator
  • RAPT 17.00
  • GDTC 21.60

About RAPT RAPT Therapeutics Inc.

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: